<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180930041185N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-11-03</date_registration>
      <primary_sponsor>National Institute for Medical Research Development</primary_sponsor>
      <public_title>Effect of the Partnership Care Model in Patients with cerebrovascular accident</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of "Partnership Care Model" on quality of life and activity daily living in Patients' Cerebrovascular accident</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/34142</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: The allocation of subjects is done by the randomization technique lottery. As 80 cards are numbered for 80 patients and placed in a basket. Then two blank envelopes are determined, one as intervention and one as control. Then, by drawing cards from the basket, some numbers are selected alternately for the two envelopes. Then the patients admitted the hospital receive a number based on their reception order (based on the cards in the pockets), Blinding description: Participants are unaware of the study groups they are allocated to.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Stroke / Cerebrovascular Accident.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients will receive stroke care and treatment based on partnership care model (PCM). After assessment and recording basic information (demographic variables, care requirements and problems highlighted in the first step of PCM), the care program will prepared and implemented for the intervention group in accordance with the PCM. The program has two phases: (i) an educational partnership meeting; and (ii) a follow-up partnership meeting. In the first phase, at least three educational partnership will be held at the rehabilitation centers weekly; the partnership comprised of 4–6 patients, a nurse and a physician. The nurse will be the leader of the team and the chair of the meetings. The physician will support the patients in decision making. The purpose of these meetings will be motivating and making the patients ready. In the first meeting, the nature, causes and complications of CVA will be introduced to the patients. The second meeting will address non-drug therapy (nutrition and activity regimens). In this meeting, nutrition and activity regimens will be arranged, evaluated and justified for each participant in response to his/her questions, level of distress, condition and status. In the third meeting drug therapy for underlying diseases such as high blood pressure and diabetes will be discussed. Prescription drugs, their effects, their usage and dosage, their importance and side effects will be discussed in addition to address patient's anxiety and answer any questions about the drugs. In the second phase, follow-up partnership meetings will be held monthly in the rehabilitation center for 6 months. These meetings will be held by the partnership of 4–6 patients, the nurse and the physician. The goal of the meetings will be to encourage, support and evaluate the patient compliance and participation during care. At each meeting, in the first 40–45 minutes, blood pressure will be taken and problems with the disease will be considered and addressed, new prescriptions or nutrition regimens will be offered, and previous medical care intervention will be evaluated. The SF-36 &amp; ADL questionnaires are also completed by patients in each session. Intervention 2: Control group: Patients in the control group include stroke patients who receive routine care at the rehabilitation center. These patients are screened and hospitalized at least one month after the attack by the physician.After determining the needs and problems of rehabilitation, physiotherapist or speech therapist referral and rehabilitation is performed, then they are discharged at most after three weeks.They will visited by a researcher at the center. These patients, like the patients in the intervention group, have been visited by a research associate to complete the questionnaires' the quality of life and the Activity of Daily Living at specified intervals.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is I must provide all information for the sponsoring institution.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Eesa  Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nasr (Ghisha) Bridge, Jalale Al-Ahmad Great way</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14115-333</zip>
        <telephone>+98 21 8288 3585</telephone>
        <email>mohamade@modares.ac.ir</email>
        <affiliation>Faculty of Medical Sciences, Tarbiat Modares University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Eesa Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bridge Nasr (Ghisha), Jalale Al-Ahmad Great Way.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14115-333</zip>
        <telephone>+98 21 8288 3585</telephone>
        <email>mohamade@modares.ac.ir</email>
        <affiliation>Faculty of Medical Sciences of Tarbiat Modares University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having at least 2 weeks history of treatment for Stroke
Being at the age of 60 years old and more
Willing to take part in the study
Ability of communication and decision making</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Heart failure (class III , IV)
Having malignancies requiring chemotherapy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I64</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Stroke, not specified as haemorrhage or infarction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients will receive stroke care and treatment based on partnership care model (PCM). After assessment and recording basic information (demographic variables, care requirements and problems highlighted in the first step of PCM), the care program will prepared and implemented for the intervention group in accordance with the PCM. The program has two phases: (i) an educational partnership meeting; and (ii) a follow-up partnership meeting. In the first phase, at least three educational partnership will be held at the rehabilitation centers weekly; the partnership comprised of 4–6 patients, a nurse and a physician. The nurse will be the leader of the team and the chair of the meetings. The physician will support the patients in decision making. The purpose of these meetings will be motivating and making the patients ready. In the first meeting, the nature, causes and complications of CVA will be introduced to the patients. The second meeting will address non-drug therapy (nutrition and activity regimens). In this meeting, nutrition and activity regimens will be arranged, evaluated and justified for each participant in response to his/her questions, level of distress, condition and status. In the third meeting drug therapy for underlying diseases such as high blood pressure and diabetes will be discussed. Prescription drugs, their effects, their usage and dosage, their importance and side effects will be discussed in addition to address patient's anxiety and answer any questions about the drugs. In the second phase, follow-up partnership meetings will be held monthly in the rehabilitation center for 6 months. These meetings will be held by the partnership of 4–6 patients, the nurse and the physician. The goal of the meetings will be to encourage, support and evaluate the patient compliance and participation during care. At each meeting, in the first 40–45 minutes, blood pressure will be taken and problems with the disease will be considered and addressed, new prescriptions or nutrition regimens will be offered, and previous medical care intervention will be evaluated. The SF-36 &amp; ADL questionnaires are also completed by patients in each session.</i_keyword>
      <i_keyword>Control group: Patients in the control group include stroke patients who receive routine care at the rehabilitation center. These patients are screened and hospitalized at least one month after the attack by the physician.After determining the needs and problems of rehabilitation, physiotherapist or speech therapist referral and rehabilitation is performed, then they are discharged at most after three weeks.They will visited by a researcher at the center. These patients, like the patients in the intervention group, have been visited by a research associate to complete the questionnaires' the quality of life and the Activity of Daily Living at specified intervals.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patients' Quality of Life Score based on SF-36 questionnaire. Timepoint: Measurements are done before the intervention, one month after completing the first phase of intervention, and then for up to 6 months, monthly in each follow-up visit. Method of measurement: Short Form- 36 (SF-36) Questionnaires related to quality of life.</prim_outcome>
      <prim_outcome>Activity of Daily Living Score based on The Lawton Criteria. Timepoint: Measurements are done before the intervention, one month after completing the first phase of intervention, and then for up to 6 months, monthly in each follow-up visit. Method of measurement: The Lawton Questionnaire to measure the ٍElderly's Activity of Daily Living.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National Institute for Medical Research Development</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-07-01</approval_date>
        <contact_name>University/Regional Research Ethics Committee</contact_name>
        <contact_address>No. 21, First Besat Ave., West Fathemi Ave. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
